What You Should Know:
– Congenica, a digital health company specializing in the provision of software and solutions for genomic data analysis and interpretation, and myTomorrows, a global platform facilitating access to pre-approval treatments and clinical trials, have partnered to expedite access to precision oncology for cancer patients worldwide.
– The strategic partnership between Congenica and myTomorrows will open new opportunities for physicians to search for access to pre-approval anti-cancer treatments and active clinical trials, specifically for patients whose cancers cannot be treated with approved treatment options.
– The program is set to launch in the first quarter of 2024 and will enable physicians to refer patients via Congenica’s Precision Oncology solution to the myTomorrows platform where they can search for applicable trials and request enrollment.
